| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 13.5 | — |
| Profit before tax | -4.8 | -20.4 |
| Net income | -4.8 | -5.2 |
| EPS (diluted, $ a share) | $-0.08 | $-0.10 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Operating margin | -96.4% |
|---|
10-Q filed with the SEC, NASDAQ: ABEO. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Abeona Therapeutics Inc.: key numbers
- Share price
- $2.60Close, Nov 17
- Market cap
- $149M
- Shares outstanding
- 57.15MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Abeona Therapeutics Inc.
All →Abeona Therapeutics Insider Faith L. Charles Buys $34.3K of Stock
Faith L. Charles bought 15,000 shares of Abeona Therapeutics Inc. at $2.29 a share, worth $34.3K in total on Nov 13, 2026. Shares held after the trade: 191,407 (+8.5%).
- Value
- $34.3K
- Shares
- 15,000
- Price
- $2.29
- Holding change
- +8.5%
- Trade date
- Nov 13, 2026
Abeona Therapeutics Financial Results
Abeona Therapeutics reported Q3 2026 financial results, highlighted by $13.5 million in net ZEVASKYN revenue, an 18% sequential increase. The company completed six ZEVASKYN treatments during the quarter and expanded its qualified treatment center network to eight sites. Additionally, Abeona announced the acquisition of a Phase 3-ready asset, APT-1011, for eosinophilic esophagitis and a $30 million PIPE financing.
- Term
- Q3 2026
“Maximizing the opportunity for ZEVASKYN remains our number one priority. During the third quarter, we continued to build the commercial foundation for ZEVASKYN, with expansion of our QTC network and more centers gaining firsthand treatment experience.”
Vish Seshadri, Ph.D., Chief Executive Officer of Abeona Therapeutics
“The acquisition of APT-1011 represents an important step in building Abeona into a diversified commercial-stage company, adding a uniquely differentiated late-stage orphan-drug asset with substantial commercial potential in a rapidly growing disease with high unmet need.”
Vish Seshadri, Ph.D., Chief Executive Officer of Abeona Therapeutics
Abeona Therapeutics Signs $20M M&A Deal with Ellodi Pharmaceuticals, L.P.
Abeona Therapeutics acquired substantially all assets related to APT-1011 (now ABO-801), a Phase 3-ready candidate for eosinophilic esophagitis, from Ellodi Pharmaceuticals. The deal was structured with $20 million in upfront equity consideration (4,494,383 shares) and no upfront cash, with Ellodi eligible for $30 million upon FDA approval and up to $30 million in sales milestones plus royalties.
- Value
- $20M
- Counterparty
- Ellodi Pharmaceuticals, L.P.
“The acquisition of ABO-801 is an important step in building Abeona into a diversified commercial-stage company with multiple opportunities for value inflection, adding an asset with substantial revenue potential in a rapidly growing disease.”
Vish Seshadri, Ph.D., Chief Executive Officer of Abeona Therapeutics
Abeona Therapeutics Chief Commercial Officer Madhav Vasanthavada Sells $25.3K of Stock
Madhav Vasanthavada, Chief Commercial Officer, sold 4,902 shares of Abeona Therapeutics Inc. at $5.16 a share, worth $25.3K in total on Sep 29, 2026. Shares held after the trade: 285,721 (-1.7%).
- Value
- $25.3K
- Shares
- 4,902
- Price
- $5.16
- Role
- Chief Commercial Officer
- Holding change
- -1.7%
- Trade date
- Sep 29, 2026
Abeona Therapeutics SVP, CLO Brendan M. O'Malley Sells $34.7K of Stock
Brendan M. O'Malley, SVP, CLO, sold 6,727 shares of Abeona Therapeutics Inc. at $5.16 a share, worth $34.7K in total on Sep 29, 2026. Shares held after the trade: 421,226 (-1.6%).
- Value
- $34.7K
- Shares
- 6,727
- Price
- $5.16
- Role
- SVP, CLO
- Holding change
- -1.6%
- Trade date
- Sep 29, 2026
Abeona Therapeutics CFO Joseph Walter Vazzano Sells $47.4K of Stock
Joseph Walter Vazzano, CFO, sold 9,191 shares of Abeona Therapeutics Inc. at $5.16 a share, worth $47.4K in total on Sep 29, 2026. Shares held after the trade: 482,888 (-1.9%).
- Value
- $47.4K
- Shares
- 9,191
- Price
- $5.16
- Role
- CFO
- Holding change
- -1.9%
- Trade date
- Sep 29, 2026